Amiodarone therapy in patients implanted with cardioverter-defibrillator for life-threatening ventricular arrhythmias

Area of Science:

• Cardiology
• Electrophysiology
• Pharmacology

Background:

• The efficacy of amiodarone in reducing implantable cardioverter-defibrillator (ICD) therapy for ventricular tachycardia or fibrillation (VT/VF) remains unclear.
• Organic heart disease patients with ICDs are at risk for VT/VF events.

Purpose of the Study:

• To evaluate if amiodarone improves clinical outcomes by decreasing ICD therapy deliveries in patients with VT/VF.
• To compare amiodarone's effectiveness against Class I anti-arrhythmic drugs and a control group.

Main Methods:

• A total of 507 patients with VT/VF and ICDs were enrolled.
• Patients were divided into three groups: Amiodarone (n=247), Class I anti-arrhythmic drug (n=103), and CONTROL (n=157).
• Outcomes assessed included total cause mortality and arrhythmic event-free survival over a mean follow-up of 38 months.

Main Results:

• The Class I anti-arrhythmic drug group showed significantly higher mortality and arrhythmic events compared to the Amiodarone group (p<0.05).
• No significant difference in arrhythmic event-free survival or mortality was observed between the Amiodarone and CONTROL groups.
• Amiodarone was associated with a decrease in left ventricular ejection fraction and side effects in 12% of patients, with no fatal events.

Conclusions:

• Amiodarone did not demonstrate a significant benefit in reducing ICD therapy or improving survival in this patient cohort.
• Potential clinical bias in drug selection may have influenced the study's findings.
• Further research is needed to clarify amiodarone's role in managing VT/VF in ICD patients.